{"commentary":{"count":21,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":14,"podcast":6,"x_thread":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05371093\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"ZUMA-22","nct_id":"NCT05371093","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=zuma-22-nct05371093. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"ZUMA-22","arms":[{"description":"Participants will receive cyclophosphamide 500 mg/m\\^2/day intravenously (IV) and fludarabine 30 mg/m\\^2/day IV lymphodepleting chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10\\^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10\\^8 anti-CD19 CAR T cells will be administered.","label":"Axicabtagene Ciloleucel","type":"EXPERIMENTAL"},{"description":"Participants will receive the investigator's choice of one of the following therapies/dosing schedules:\n\n* Rituximab plus lenalidomide (R\\^2) for 12 cycles (28-day cycle)\n\n  * Cycle 1: lenalidomide 20 mg/day on Day 1 through Day 21; rituximab 375 mg/m\\^2 on Day 1, Day 8, Day 15, and Day 22\n  * Cycle 2 through Cycle 5: lenalidomide 20 mg/day on Day 1 through Day 21; Rituximab 375 mg/m2 on Day 1\n  * Cycle 6 through Cycle 12: lenalidomide 20 mg/day on Day 1 through Day 21\n* Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles (21-day cycle)\n\n  * rituximab 375 mg/m\\^2 on Day 1\n  * cyclophosphamide 750 mg/m\\^2 on Day 1\n  * doxorubicin 50 mg/m\\^2 on Day 1\n  * vincristine 1.4 mg/m\\^2 (maximum 2 mg) on Day 1\n  * prednisone 40 mg/m\\^2 on Day 1 through Day 5\n* Rituximab plus bendamustine (BR) for 6 cycles (28-day cycle)\n\n  * rituximab 375 mg/m\\^2 on Day 1\n  * bendamustine 90 mg/m\\^2 on Day 1 and Day 2","label":"Standard of Care Therapy","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2030-10","type":"ESTIMATED"},"conditions":["Relapsed/Refractory Follicular Lymphoma"],"enrollment":{"count":231,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Axicabtagene Ciloleucel","type":"BIOLOGICAL"},{"name":"Cyclophosphamide","type":"DRUG"},{"name":"Fludarabine","type":"DRUG"},{"name":"Lenalidomide","type":"DRUG"},{"name":"Rituximab","type":"DRUG"},{"name":"Doxorubicin","type":"DRUG"},{"name":"Vincristine","type":"DRUG"},{"name":"Prednisone","type":"DRUG"},{"name":"Bendamustine","type":"DRUG"}],"last_update":"2025-10-15","lead_sponsor":"Kite, A Gilead Company","official_title":"A Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects With Relapsed/Refractory Follicular Lymphoma","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2030-10","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Progression-free Survival (PFS) as Assessed by Blinded Central Assessment per Lugano Classification","timeFrame":"Up to 5 years"}],"references":[],"start_date":{"date":"2022-09-22","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","url":"https://clinicaltrials.gov/study/NCT05371093"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/zuma-22-nct05371093"}